Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. - Wikidata - awgldk - TriplyDB

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.

http://www.wikidata.org/entity/Q34541113

about

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Neuroblastoma: issues in transplantation Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy.Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.GD2-targeted immunotherapy and radioimmunotherapy Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.Comparison of GD2 binding capture ELISA assays for anti-GD2-antibodies using GD2-coated plates and a GD2-expressing cell-based ELISA Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma.Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma Anti-CD3 × anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets.Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.Ocular side effects of biological agents in oncology: what should the clinician be aware of?Inflammation: what role in pediatric cancer?Glycans as targets for therapeutic antitumor antibodies.Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms.New immunotherapeutic strategies for the treatment of neuroblastoma.Dinutuximab: first global approval.Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting.Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice.Management of Neuroblastoma: ICMR Consensus Document.MYCN-targeting vaccines and immunotherapeutics.Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Surgical treatment of neuroblastoma: twenty-three years of experience at a single institution.Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.Anti-GD2 immunotherapy for neuroblastoma.Autologous cord blood transplantation for metastatic neuroblastoma.Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO.Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience.The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.Trial watch: Monoclonal antibodies in cancer therapy

P2860

Q21131216-055C971E-8D07-4910-B480-66874BF88435 Q26993238-FA3BBD89-5111-4271-8662-6B5AC389BD9B Q27008197-3CC4124E-8B63-4AD1-8F3F-B21D5A7E2C47 Q30916013-D3BDF7F7-6A57-4B55-A7F6-5EB29E3D81D4 Q33597441-9D080A03-4DF8-4BC0-8403-A95BF66B58BD Q34625339-1E443A7F-9C27-4F0F-B4E6-C926557A1B4B Q35255233-1844B506-762B-4D61-8EC1-A8C9D51FB0A3 Q35381031-F6A4FE13-B440-4E6E-A787-E954962EEDC4 Q35604043-A0D35DE8-99B5-458F-B9C1-3FDEDA35ECB8 Q35963440-27A11AA7-90BF-443E-9047-B19E4B6B3256 Q36910335-AE05D15B-D76E-4F87-9BE6-7619006056CF Q37078946-B9B47F91-670F-44D5-8AE1-1D5DAA640ED0 Q37220750-7430C88C-31A4-4FAC-AC86-E18478D4DF03 Q37364364-E1EEC70D-914F-4C19-B602-A6674475C511 Q37427522-D3F0CE02-11BB-4FE1-BB8E-70CDFADAF6CA Q37967667-0C497A8A-7C30-4E0E-A2BD-E546BF6A5D1D Q38034815-AD7ACD7A-0BB8-41A0-9527-949067B82FA4 Q38079519-89B54EE1-A8D9-43DA-877B-B09E148F0040 Q38161274-769410FB-A8DC-4FDD-91B4-818C1F657C52 Q38243215-EBA4F437-DBE3-4FE2-96CE-15C51C7ED2B0 Q38389316-5CA12325-034F-41AE-91C3-C2F1B4B536D1 Q38458853-FCB25B47-8E1A-4686-AED1-47A24A5ECBA2 Q38757939-24651653-B193-4742-9374-8031CD92E577 Q38804821-4431ECF5-BA1C-4BBA-B02B-A7F8BFE2C000 Q38916529-BFD769E6-0FCA-40D3-959A-575FB4689D74 Q39089535-2EC30F15-195C-48E8-82D5-EABDD02DFD6D Q39214599-6495366C-0D3B-4320-AD7E-47D004963A1C Q41118615-88A0B8DB-9752-478A-B5DE-2253E5F9232D Q41250708-B10B351B-3B21-44DA-AA91-5A3025569F74 Q42558833-B81767C8-F67B-4EBF-B4AF-32CDB22F7206 Q43478910-F997975E-21C8-46E2-9DE3-A0CA7C5EAD51 Q44123857-BF9DACB4-B2E9-42F7-A6A3-31468592F29D Q47108370-1DCE70E5-AF1E-4EAA-990B-D151ABA82479 Q47554435-0DE53CC6-5D60-4112-87F0-62B8E62B7B93 Q49114959-420F1B45-163C-4B0A-AE4D-531D1BDFB2C1 Q49888224-3A96BC47-0741-4F40-A89D-4BC927671BE0 Q50357815-C266912A-F14B-4330-8764-22AC7FC37583 Q51211840-A55F4455-A310-4078-BDCE-CD5A2A61DC20 Q56932681-B81DDB50-F46A-4559-97AE-17DEC0D8564E

P2860

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy.

http://www.wikidata.org/entity/Q34541113

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@ast

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@en

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@nl

type

label

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@ast

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@en

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@nl

prefLabel

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@ast

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@en

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@nl

P1433

Q34541113-F92B2F7D-F648-4411-B8A2-A867BE615C36

P1476

Q34541113-DE7C9096-194E-480F-BB3B-B8ED39117278

P2093

Q34541113-35134CB6-0867-40CD-8765-7E071C7B2453

Q34541113-4F4DF7B0-889A-44AE-A021-8169B66D7593

Q34541113-9A79B24B-3B4C-4FF6-8A0C-62B0BA49676F

Q34541113-C05AB4A3-E12F-4A1F-97FA-60FD90918BE0

Q34541113-C3C2B392-4C2C-424F-B793-8C2DC4611824

P2860

Q34541113-0C1F38DE-CA26-42AD-A524-73AFB30F759F

Q34541113-328B36E5-F5BA-46E3-B1EC-3B077660320E

Q34541113-5BD26468-FD3C-4C2D-8539-955ED08BA07D

Q34541113-5CD09F55-F903-4BB2-8C2E-10214F716655

Q34541113-6B610B1F-EBEB-451D-AF51-EFC3BF55B536

Q34541113-94E494D5-CAF5-43C3-978D-773E08E998D8

Q34541113-9CA54619-6333-41C6-951E-90AA44B89763

Q34541113-A2DC23F7-889C-419C-B97B-7E264133A569

Q34541113-B05B3D76-7DAB-4C43-855D-5C8E24E31E68

Q34541113-C92A04E3-9EC1-4BF9-8334-4BBF244776A5

P2888

Q34541113-E5452EFF-DC34-48B8-8C22-E5B13B09EBEC

P304

Q34541113-51A86EB8-B40B-45E4-90F5-8821C4D140D1

P31

Q34541113-68A94F31-4206-4AA7-9A5E-C9E5AAF1491C

P356

Q34541113-B0F09DE1-FC09-4FBB-B79C-5AC1312FF0D7

P407

Q34541113-900D3ED2-0608-440E-8B19-F08253B0CE2C

P478

Q34541113-3F0FD1FE-3C41-4BCF-A820-622FA71E1C83

P50

Q34541113-C5BE5330-05F2-4A34-8763-1652FFF432C9

Q34541113-FE9D9364-11C9-44DF-B539-8B9AE732498E

P577

Q34541113-ECD5A01E-CD6E-4ED6-A0D1-C867075792CD

P5875

Q34541113-C211ABF9-66D1-47F0-8929-3D24158D0C0B

P6179

Q34541113-9A403CBD-379F-43A8-BBFE-E32DB21BAA0A

P698

Q34541113-BBCEA385-EC80-4318-B347-444C27559FEF

P921

Q34541113-4DB8EC38-D2E4-437E-A04D-6B71F6B0B755

Q34541113-9599C9CE-D3C7-4698-87CA-7520025E8E65

Q34541113-B47CB684-A313-40FE-968E-E0AF77FA1EE6

Q34541113-D84C48B0-22E0-4277-9519-4174A0AE697D

P932

Q34541113-422BA314-4382-4BAA-BD1F-44C4A954B559

P356

1471-2407-11-21

P1433

P1476

Long term outcome of high-risk ...... oral metronomic chemotherapy.

@en

P2093

Andreas Faldum

http://www.w3.org/2001/XMLSchema#string

Barbara Hero

http://www.w3.org/2001/XMLSchema#string

Frank Berthold

http://www.w3.org/2001/XMLSchema#string

Rupert Handgretinger

http://www.w3.org/2001/XMLSchema#string

Thorsten Simon

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.

Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma.

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy.

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.

Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.

P2888

1471-2407-11-21

P304

21

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-11-21

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Klingebiel

Martin Schrappe

P577

2011-01-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49764685

http://www.w3.org/2001/XMLSchema#string

P6179

1046480488

http://www.w3.org/2001/XMLSchema#string

P698

21244693

http://www.w3.org/2001/XMLSchema#string

P921

P932

3031264

http://www.w3.org/2001/XMLSchema#string